PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive OfficerPORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer

FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA.

With more than a decade of expertise, FJBio has supported over 250 clients across Pharma, Biotech and Academia and contributed to more than 19 antibodies advancing to clinical stage development or the market. During his presentation, Dr. Lanthaler will address FJBio’s strategic positioning as a highly efficient, integrated partner. He will showcase the Company’s antibody discovery and development solutions, with a focus on innovation, data-driven platforms and scalable collaboration models across the biopharmaceutical ecosystem.

Presenter

Role

Date

Time

Venue

Dr. Werner Lanthaler

CEO, FJBio

Jan 13

09:00–09:25 AM

“Golden Gate” at THE WESTIN, 32nd floor

In addition to the CEO presentation, members of FJBio’s Senior Management and Business Development teams will attend the conference for strategic discussions with representatives of global pharmaceutical companies, biotechnology innovators and other industry partners throughout the event.

Dr. Werner Lanthaler, Chief Executive Officer of FairJourney Bio, commented: “I look forward to presenting FairJourney Bio’s unique platform for partnered pipeline building at this year’s J.P. Morgan 2026 Healthcare Conference. This conference brings together a highly curated group of global healthcare leaders and innovators and I appreciate the opportunity to engage in meaningful dialogue around the future of efficient, data-enabled antibody discovery and development.”

Participation as a presenting company at this conference is highly selective and considered a significant distinction, reflecting FJBio’s growing global recognition and relevance within the international life sciences community. The conference provides an important platform for FJBio to strengthen existing relationships, explore new strategic partnerships and further position the Company as a trusted global partner across the full value chain.

Contacts

FairJourney Biologics
Hinnerk Rohwedder

Head of Marketing & Communications

hrohwedder@fjbio.com

Zyme Communications

Lily Jeffery
Email: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

Market Opportunity
BIO Protocol Logo
BIO Protocol Price(BIO)
$0.03838
$0.03838$0.03838
-3.51%
USD
BIO Protocol (BIO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Republic Europe Offers Indirect Kraken Stake via SPV

Republic Europe Offers Indirect Kraken Stake via SPV

Republic Europe launches SPV for European retail access to Kraken equity pre-IPO.
Share
bitcoininfonews2026/01/30 13:32
cpwrt Limited Positions Customer Support as a Strategic Growth Function

cpwrt Limited Positions Customer Support as a Strategic Growth Function

For many growing businesses, customer support is often viewed as a cost center rather than a strategic function. cpwrt limited challenges this perception by providing
Share
Techbullion2026/01/30 13:07
How is the xStocks tokenized stock market developing?

How is the xStocks tokenized stock market developing?

Author: Heechang Compiled by: TechFlow xStocks offers a tokenized stock service, allowing investors to trade tokenized versions of popular US stocks like Tesla in real time. While still in its early stages, it’s already showing some interesting signs of growth. Observation 1: Trading is concentrated in Tesla (TSLA) As in many emerging markets, trading activity has quickly concentrated on a handful of stocks. Data shows a high concentration of trading volume in the most well-known and volatile stocks, with Tesla being the most prominent example. This concentration is not surprising: liquidity tends to accumulate in assets that retail investors already favor, and early adopters often use familiar high-beta stocks to test new infrastructure. Observation 2: Liquidity decreases on weekends Data shows that on-chain equity trading volume drops to 30% or less of weekday levels over the weekend. Unlike crypto-native assets, which trade seamlessly around the clock, tokenized stocks still inherit the behavioral inertia of traditional market trading hours. Traders appear less willing to trade when reference markets (such as Nasdaq and the New York Stock Exchange) are closed, likely due to concerns about arbitrage, price gaps, and the inability to hedge positions off-chain. Observation 3: Prices move in line with the Nasdaq Another key signal comes from pricing behavior during the initial launch period. Initially, xStocks tokens traded at a significant premium to their Nasdaq counterparts, reflecting market enthusiasm and potential friction in bridging fiat liquidity. However, these premiums gradually diminished over time. Current trading patterns show that the token price is at the upper limit of Tesla's intraday price range and is highly consistent with the Nasdaq reference price. Arbitrageurs appear to be maintaining this price discipline, but there are still small deviations from the intraday highs, indicating some market inefficiencies that may present opportunities and risks for active traders. New opportunities for Korean stock investors? South Korean investors currently hold over $100 billion in US stocks, with trading volume increasing 17-fold since January 2020. Existing infrastructure for South Korean investors to trade US stocks is limited by high fees, long settlement times, and slow cash-out processes, creating opportunities for tokenized or on-chain mirror stocks. As the infrastructure and platforms supporting on-chain US stock markets continue to improve, a new group of South Korean traders will enter the crypto market, which is undoubtedly a huge opportunity.
Share
PANews2025/09/18 08:00